Previous reports have shown that RAD51 is overexpressed in several cancers, including breast, pancreatic, non-small cell lung and prostate cancer expression, and is associated with lower overall survival in breast cancer [28], likely reflecting the contribution of RAD51 to HRR and consequent resistance to conventional cancer treatments [29]. Here, RAD51 is linked to breast carcinoma.